Oral sodium phosphate (OSP) products are commonly taken before a colonoscopy to help clean out your system and aid in the effectiveness of your procedure. However, recent evidence has linked OSPs to an increased risk of kidney damage.
After receiving reports of more than 20 patients suffering serious kidney injuries from taking OSPs, the Food and Drug Administraton (FDA) has required pharmaceutical manufacturers to place a black box warning on their OSP products. Black box warnings are the strongest safety warnings administered by the FDA.
One of the OSPs linked to kidney problems is OsmoPrep, a prescription tablet manufactured by Salix Pharmaceuticals. OsmoPrep became a popular option for patients, since it is taken in tablet form and therefore does not have the unpleasant taste associated with many of the liquid OSPs on the market. However, OsmoPrep has been linked to the development of acute phosphate nephropathy, a rare kidney disorder.
Acute Phosphate Nephropathy
Acute phosphate nephropathy is a serious condition caused by the build-up of calcium phosphate crystals in your renal tubules. It can lead to permanent kidney damage, and you may require chronic dialysis. Patients most at risk for developing acute phosphate nephropathy include those who:
- Are age 55 and older
- Have decreased intravascular volume or kidney disease
- Use medication affecting renal functioning (diuretics, angiotensin converting enzyme ACE inhibitors, angiotensin receptor blockers ARBs, and nonsteroidal anti-inflammatory drugs NSAIDS)
If you have developed acute phosphate nephropathy or any other kidney condition from taking OsmoPrep, you may have a valid pharmaceutical liability claim. The attorneys at Carr & Carr can help you receive the compensation you deserve for the injuries you have suffered.
Please contact the pharmaceutical liability lawyers at Carr & Carr Attorneys at Law today to schedule a consultation.